Literature DB >> 12838269

Clinical biomarkers in drug discovery and development.

Richard Frank1, Richard Hargreaves.   

Abstract

Biomarkers enable the characterization of patient populations and quantitation of the extent to which new drugs reach intended targets, alter proposed pathophysiological mechanisms and achieve clinical outcomes. In genomics, the biomarker challenge is to identify unique molecular signatures in complex biological mixtures that can be unambiguously correlated to biological events in order to validate novel drug targets and predict drug response. Biomarkers can stratify patient populations or quantify drug benefit in primary prevention or disease-modification studies in poorly served areas such as neurodegeneration and cancer. Clinically useful biomarkers are required to inform regulatory and therapeutic decision making regarding candidate drugs and their indications in order to help bring new medicines to the right patients faster than they are today.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12838269     DOI: 10.1038/nrd1130

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  153 in total

1.  BPDA2d--a 2D global optimization-based Bayesian peptide detection algorithm for liquid chromatograph-mass spectrometry.

Authors:  Youting Sun; Jianqiu Zhang; Ulisses Braga-Neto; Edward R Dougherty
Journal:  Bioinformatics       Date:  2011-12-06       Impact factor: 6.937

2.  Minimum data elements for research reports on CFS.

Authors:  Leonard A Jason; Elizabeth R Unger; Jordan D Dimitrakoff; Adam P Fagin; Michael Houghton; Dane B Cook; Gailen D Marshall; Nancy Klimas; Christopher Snell
Journal:  Brain Behav Immun       Date:  2012-01-28       Impact factor: 7.217

3.  Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling.

Authors:  Simone Nicolardi; Magnus Palmblad; Hans Dalebout; Marco Bladergroen; Rob A E M Tollenaar; André M Deelder; Yuri E M van der Burgt
Journal:  J Am Soc Mass Spectrom       Date:  2010-05-12       Impact factor: 3.109

Review 4.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

5.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

6.  Translational medicine: can it really facilitate the transition of research "from bench to bedside"?

Authors:  Martin Wehling
Journal:  Eur J Clin Pharmacol       Date:  2005-12-13       Impact factor: 2.953

7.  Biases in Multicenter Longitudinal PET Standardized Uptake Value Measurements.

Authors:  Robert K Doot; Larry A Pierce; Darrin Byrd; Brian Elston; Keith C Allberg; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

8.  A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Authors:  Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 10.  Combining targeted therapies: practical issues to consider at the bench and bedside.

Authors:  Jordi Rodon; Jose Perez; Razelle Kurzrock
Journal:  Oncologist       Date:  2010-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.